Introduction
Modern medicine requires a clear and explicit criteria to describe the phenomena of public health; and one of the major problems of public health is drug resistance of microorganisms.
Objectives
The aim of this study was to analyze how big epidemiological problem are highly-resistantmultidrugresistant (MDR) and extensively-drug resistant (XDR) non-fermentative bacilli isolated from bloodstream infections (BSI) in southern Poland.
Methods
The study comprised consecutive, non-repetitive nonfermentative bacilli (NFB) isolates received by the Chair of Microbiology UJCM with collaborative 2 laboratories in 2013 from BSI of hospitalized (12 hospitals) throughout south of Poland (Malopolska and Silesia).
Studied strains from BSI were belonging to groups: ACI (Acinetobacter baumannii n=21, Acinetobacter lwoffii n=1, Acinetobacter ursingi n=1), PAR (Pseudomonas aeruginosa n=12), and others (Stenotrophomonas malthophilia n=10, Achromobacter denitrificans n=5, Comamonas testosterone n=1, Ochrobactrum anthropi n=1).
Antimicrobial susceptibility was assessed according to current EUCAST guidelines. Different patterns of resistance were defined according to Magiorakos (2012) as: MDR strains or XDR.
Results
NFB strains occurred with different frequencies, the highest prevalence was associated with ACI: 1.3%.
More than 75% of ACI strains were resistant to 14 out of 16 antimicrobials, among ACI also found the highest share of XDR: 95.7%. The most of these isolates were resistant to all antibiotics with the exception of colistin: MIC50 for colistin was 1.
In the group of PAR isolates 91.7% were XDR, MIC50 for colistin was 1.
DiversiLab typing demonstrated the presence of two dominant ACI clones. Clone 1 and clone 2 , both are classified as the European clone 2 (EUII).
Conclusion
The presented data indicate a high potential therapeutic problems related to the large resistance of ACI isolates. The used stratification of drug resistance (MDRO/XDR/ PDR) may become an important tool for the assessment of public health and microbiological hazards at different levels. (supported by DEC-2012/05/B/NZ7/02880).
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